![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Enzymotec Ltd. - Ordinary Shares (delisted) | NASDAQ:ENZY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.85 | 0.05 | 199,999.95 | 0 | 01:00:00 |
Bengt Jöndell has been appointed Acting CFO of Enzymatica with effect from 4 April. Johan Wennerholm, Enzymatica's current CFO, has decided to leave the company to take up an appointment as CEO of a company outside the Group. The recruitment process for a new CFO has begun. Johan Wennerholm will remain with the company for the next few months to facilitate the hand-over to Bengt Jöndell.
Bengt's most recent post was as CFO and Administrative Manager at BTJ Group AB. Before that, his appointments included Senior Financial Advisor at the med tech company, BoneSupport, CFO/Administrative Manager at Inpac, Business Controller at Pharmacia & Upjohn Consumer Healthcare, Pharmacia Consumer Pharma and Kabi Pharmacia Nicorette.
"Bengt Jöndell has an excellent background for an Acting CFO, with 25 years' experience of finance, HR, IT and
management from international companies, part of that in pharmaceuticals," said Fredrik Lindberg, CEO of Enzymatica. Fredrik continued:
"Johan Wennerholm has done an outstanding job at Enzymatica, including leading the listing process on Nasdaq First North. He has made a highly significant contribution to the company's progress in areas such as finance and administration. I wish him every success with his new challenges."
For more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: 0708-86 53 70 | E-mail: fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.
Enzymatica's certified adviser is Erik Penser Bankaktiebolag.
1 Year ENZYMOTEC LTD. Chart |
1 Month ENZYMOTEC LTD. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions